The Pharma Deal Of The Year Is…
Nothing like a drying tube to spur an acquisition, or an alliance, or a licensing buy. And there were certainly enough in 2008, given the dire straits confronting many strapping drugmakers. But which deal was truly guileful, captivating and, most of all, potentially lucrative?
What about the tie-up between Pfizer and Ranbaxy? Pfizer walked away with dividend 20 months of Lipitor patent exclusivity and Ranbaxy got the proper to sell generic versions in November 2011 in the US, and flog betray generics in some other countries. How about Lilly scooping up ImClone Systems? Or the Novartis diversification move to pay $11 billion for 25 percent of Alcon?
Well, the In Vivo blog, which tracks such things closely all year fancy, is running a poll. So you can decide for yourselves honesty here. And no, only consummated deals count, even if the Roche move to buy the have a zizz of Genentech does offer some engrossing drama.